🇺🇸 FDA

Intelligence · Clinical Pipeline

Oncology R&D Pipeline

Anticancer agents, immuno-oncology biologics, and oncology pipeline programs from ClinicalTrials.gov — Phase 1 through approval.

Programs
5,568

Quick answer

Oncology: NovaPharmaNews indexes 5,568 oncology clinical pipeline programs from ClinicalTrials.gov with phase, modality, NCT identifiers, and sponsor company links. Anticancer agents, immuno-oncology biologics, and oncology pipeline programs from ClinicalTrials.gov — Phase 1 through approval.

Top sponsors

Page 51 of 116

  1. IMFINZI 50 mg/mL concentrate for solution for infusion., Ampligen

    Disc Medicine

    Metastatic pancreatic cancer

    phase 2 small molecule active

    1 trial

  2. IMFINZI 50 mg/mL concentrate for solution for infusion., BEVACIZUMAB, IMJUDO 20 mg/ml concentrate for solution for infusion.

    AstraZeneca AB

    Hepatocellular Carcinoma

    phase 2 small molecule active

    1 trial

  3. IMFINZI 50 mg/mL concentrate for solution for infusion., CAPECITABINE , TREMELIMUMAB

    The George Institute

    Biliary tract cancer

    phase 2 small molecule active

    1 trial

  4. IMFINZI 50 mg/mL concentrate for solution for infusion., CARBOPLATIN , IMFINZI 50 mg/mL concentrate for solution for infusion., IMFINZI 50 mg/mL concentrate for solution for infusion., PEMETREXED , PACLITAXEL , IMFINZI 50 mg/mL concentrate for solution for infusion., IPH5201, CISPLATIN

    Lacuna Pharma Pty Ltd

    Non-Small Cell Lung Cancer II, III

    phase 2 small molecule active

    1 trial

  5. IMFINZI 50 mg/mL concentrate for solution for infusion., CISPLATIN

    Ningbo Cancer Hospital

    Oropharyngeal Squamous Cell Carcinoma

    phase 2 small molecule active

    1 trial

  6. IMFINZI 50 mg/mL concentrate for solution for infusion., Ceralasertib, Inflectra 100 mg powder for concentrate for solution for infusion, Mycophenolate Mofetil 250 mg Capsules

    AstraZeneca AB

    Unresectable or Advanced Melanoma

    phase 2 small molecule active

    1 trial

  7. IMFINZI 50 mg/mL concentrate for solution for infusion., FLUOROURACIL, FOLINIC ACID, OXALIPLATIN

    Ningbo Cancer Hospital

    Localised unresectable adenocarcinoma or squamous cell carcinoma of the oesophagus without any prior chemotherapy, surgery, or radiotherapy

    phase 2 small molecule active

    1 trial

  8. IMFINZI 50 mg/mL concentrate for solution for infusion., IMJUDO 20 mg/ml concentrate for solution for infusion.

    The George Institute

    Metastatic squamous cell carcinoma of head and neck, lung, esophagus, cervix, vagina, vulva or anus to be treated with SBRT

    phase 2 small molecule active

    1 trial

  9. IMFINZI 50 mg/mL concentrate for solution for infusion., IMJUDO 20 mg/ml concentrate for solution for infusion.

    AstraZeneca AB

    Advanced Solid Tumors

    phase 2 small molecule active

    1 trial

  10. IMFINZI 50 mg/mL concentrate for solution for infusion., INFLIXIMAB, Lynparza 100 mg film-coated tablets, MYCOPHENOLATE MOFETIL, Lynparza 150 mg film-coated tablets

    AstraZeneca AB

    BRCA Mutations and Early Stage HER2-Negative Breast Cancer

    phase 2 small molecule active

    1 trial

  11. IMFINZI 50 mg/mL concentrate for solution for infusion., TREMELIMUMAB

    Pari Pharma GmbH

    Hepatocellular carcinoma

    phase 2 small molecule active

    1 trial

  12. IMFINZI 50 mg/mL concentrate for solution for infusion., TREMELIMUMAB

    The George Institute

    Intermediate stage hepatocellular carcinoma (HCC)

    phase 2 small molecule active

    1 trial

  13. IMFINZI 50 mg/mL concentrate for solution for infusion., Tecentriq 1 200 mg concentrate for solution for infusion, IMFINZI 50 mg/mL concentrate for solution for infusion., Tecentriq 840 mg concentrate for solution for infusion

    Partner Therapeutics Limited

    Extensive-disease small cell lung cancer and high SLFN11-expression

    phase 2 small molecule active

    1 trial

  14. IMJUDO 20 mg/ml concentrate for solution for infusion., IMFINZI 50 mg/mL concentrate for solution for infusion.

    The George Institute

    Advanced stage intrahepatic biliary tract cancer (BTC)

    phase 2 small molecule active

    1 trial

  15. IMP1734

    Eikon Therapeutics

    Advanced Solid Tumor

    phase 2 small molecule active

    1 trial

  16. IMX-110 combined with Tislelizumab

    Immix Biopharma

    Advanced Solid Tumor

    phase 2 small molecule active

    1 trial

  17. IN10018

    Hospital Authority, Hong Kong

    Cervical Adenocarcinoma

    phase 2 small molecule active

    1 trial

  18. INAVOLISIB

    Fondazione Telethon ETS

    endometrial cancer

    phase 2 small molecule active

    1 trial

  19. INAVOLISIB, DOCETAXEL, INAVOLISIB, ENZALUTAMIDE, ENZALUTAMIDE, ABIRATERONE

    Hoffmann-La Roche

    Metastatic Castration-Resistant Prostate Cancer

    phase 2 small molecule active

    1 trial

  20. INAVOLISIB, FULVESTRANT, INAVOLISIB

    Hoffmann-La Roche

    Phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha gene (PIK3CA)-Mutated, hormone receptor-positive (HR-Positive), human epidermal growth factor receptor 2 (HER2)-Negative Locally Advanced or Metastatic Breast Cancer

    phase 2 small molecule active

    1 trial

  21. INAVOLISIB, RIBOCICLIB, INAVOLISIB, RIBOCICLIB, Inavolisib placebo, FULVESTRANT

    Hoffmann-La Roche

    Endocrine-Resistant Hormone-Receptor-Positive, HER2-Negative Advanced Breast Cancer with Chromosome 8p Loss and Without PIK3CA Mutation

    phase 2 small molecule active

    1 trial

  22. INAVOLISIB, RO 743-5846/F04, RO7223619, INAVOLISIB, RO 743-5846/F07, Ipatasertib, Rozlytrek 200 mg hard capsules, Alecensa 150 mg hard capsules, Rozlytrek 100 mg hard capsules, Tecentriq 1 200 mg concentrate for solution for infusion, INAVOLISIB, Rozlytrek, Ipatasertib, Camonsertib, INAVOLISIB, RO 749-9790/F02-02

    Hoffmann-La Roche

    Solid tumors

    phase 2 small molecule active

    1 trial

  23. INBRX-106 - Hexavalent OX40 agonist antibody

    Inhibrx Biosciences

    Solid Tumor

    phase 2 small molecule active

    1 trial

  24. INBRX-109

    Inhibrx Biosciences

    Conventional Chondrosarcoma

    phase 2 small molecule active

    1 trial

  25. INC280

    Novartis Pharmaceuticals

    Non-small Cell Lung Cancer

    phase 2 small molecule completed

    1 trial

  26. INC280, INC280, JNJ-61186372

    Janssen-Cilag International N.V.

    Unresectable Metastatic Non-small Cell Lung Cancer

    phase 2 small molecule active

    1 trial

  27. INCB099280, Adagrasib

    Incyte

    Advanced Solid Tumors Harboring a KRASG12C Mutation

    phase 2 small molecule active

    1 trial

  28. INDOCYANINE GREEN

    Fondazione Telethon ETS

    Patients with gynecological cancers undergoing pelvic exenteration

    phase 2 small molecule active

    1 trial

  29. INDOCYANINE GREEN

    The George Institute

    Patients with primary invasive early breast cancer (T1-T2) that will undergo planned breast-conserving surgery

    phase 2 small molecule active

    1 trial

  30. INFLIXIMAB, DS-8201a, IMFINZI 50 mg/mL concentrate for solution for infusion., MYCOPHENOLATE MOFETIL, PERTUZUMAB

    AstraZeneca AB

    HER2-positive Metastatic Breast Cancer

    phase 2 small molecule active

    1 trial

  31. INFLIXIMAB, FOLINIC ACID, IRINOTECAN HYDROCHLORIDE TRIHYDRATE, CALCIUM FOLINATE, MYCOPHENOLATE MOFETIL, volrustomig, FLUOROURACIL, BEVACIZUMAB

    AstraZeneca AB

    ​​Colorectal cancer​

    phase 2 small molecule active

    1 trial

  32. INO-3112

    INOVIO PHARMACEUTICALS, INC.

    Head and Neck Squamous Cell Cancer

    phase 2 mab completed

    1 trial

  33. INO-3112

    INOVIO PHARMACEUTICALS, INC.

    Cervical Cancer

    phase 2 mab completed

    1 trial

  34. INO-3112 vaccine

    INOVIO PHARMACEUTICALS, INC.

    Uterine Cervical Neoplasms

    phase 2 mab terminated

    1 trial

  35. INO-5401

    INOVIO PHARMACEUTICALS, INC.

    Urothelial Carcinoma

    phase 2 mab completed

    1 trial

  36. INT230-6

    INTENSITY THERAPEUTICS, INC.

    Breast Cancer

    phase 2 small molecule active

    2 trials

  37. INXN-2001

    Alaunos Therapeutics

    Melanoma

    phase 2 mab completed

    1 trial

  38. IO102-IO103

    IO Biotech

    Melanoma

    phase 2 small molecule active

    2 trials

  39. IO102-IO103 in combination with pembrolizumab

    IO Biotech

    Lung Cancer Non Small Cell

    phase 2 small molecule completed

    1 trial

  40. IO102-IO103, KEYTRUDA 25 mg/mL concentrate for solution for infusion

    IO Biotech

    Metastatic Squamous Cell Carcinoma of Head and Neck (SCCHN), Metastatic Urothelial Bladder Cancer (mUBC), Metastatic Non-Small Cell Lung Cancer (NSCLC)

    phase 2 small molecule active

    1 trial

  41. IONIS-STAT3Rx

    IONIS PHARMACEUTICALS INC

    Advanced Cancers

    phase 2 small molecule completed

    1 trial

  42. IOV-3001

    Iovance Biotherapeutics B.V.

    Unresectable Melanoma

    phase 2 mab active

    1 trial

  43. IOV-4001

    Iovance Biotherapeutics B.V.

    Unresectable Melanoma

    phase 2 mab active

    1 trial

  44. IPH6501

    Lacuna Pharma Pty Ltd

    Relapsed and/or Refractory CD20-expressing Non-Hodgkin Lymphoma

    phase 2 small molecule active

    1 trial

  45. IPILIMUMAB, AXITINIB, PF-08634404, AXITINIB

    Pfizer Australia Pty Ltd

    ADVANCED OR METASTATIC RENAL CELL CARCINOMA

    phase 2 small molecule active

    1 trial

  46. IPILIMUMAB, NIVOLUMAB

    Ningbo Cancer Hospital

    type B3 thymoma and thymic carcinoma

    phase 2 small molecule active

    1 trial

  47. IPN01203

    Ipsen

    Advanced Solid Tumor, Metastatic Solid Tumor

    phase 2 small molecule active

    1 trial

  48. IRINOTECAN, CALCIUM LEVOFOLINATE, ivonescimab, FOLINIC ACID, OXALIPLATIN, PACLITAXEL, FLUOROURACIL

    Ningbo Cancer Hospital

    Metastatic or locally advanced irresectable (stage IV) gastric cancer (GC) or esophagogastric junction cancer (EGJC), with and without actionable biomarker (HER2/Claudin18.2)

    phase 2 small molecule active

    1 trial

Frequently asked questions

How many oncology pipeline programs are tracked?

5,568 programs match this therapeutic area based on indication text, program name, and registry metadata.

Where does pipeline data come from?

ClinicalTrials.gov records linked to NovaPharmaNews company profiles. Verify on ClinicalTrials.gov before investment decisions.

Data attribution: Data sources · All pipeline programs

Drug approvals, clinical trials, M&A, event intelligence, and company updates — weekly.

Customize topics & region
Topics
Region

No spam. Unsubscribe anytime. See our privacy policy.